D. Ritchie

发表

Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.

Nareshkumar Jain, Jiayi Xu, R. Kanojia, 2009, Journal of medicinal chemistry.

Applied Pharmacokinetics in Drug Development

D. Ritchie, Zhengyin Yan, G. Leo, 2003 .

Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.

Martin Cousineau, Sean X Peng, D. Ritchie, 2006, Journal of pharmaceutical sciences.

The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens

D. Ritchie, G. Caldwell, J. Masucci, 2012, European Journal of Drug Metabolism and Pharmacokinetics.

1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxygenase-2.

D. Ritchie, Z. Sui, W. Murray, 2000, Bioorganic & medicinal chemistry letters.

1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxygenase-2.

D. Ritchie, Z. Sui, W. Murray, 2000, Bioorganic & medicinal chemistry letters.

Novel 6-oxo-6-naphthylhexanoic acid derivatives with anti-inflammatory and 5-lipoxygenase inhibitory activity

D. Ritchie, W. Murray, M. Wachter, 1991 .

N-(5-substituted) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase.

T. Kirchner, D. Ritchie, M. Singer, 1997, Bioorganic & medicinal chemistry.

SRSA-mediated bronchospasm by pharmacologic modification of lung anaphylaxis in vivo

D. Ritchie, R. Capetola, M. Rosenthale, 1981, Agents and Actions.

Smooth muscle contraction as a model to study the mediator role of endogenous lipoxygenase products of arachidonic acid.

D. Hahn, D. Ritchie, J. Mcguire, 1984, Life sciences.

Involvement of lipoxygenase products in myometrial contractions.

D. Hahn, D. Ritchie, J. Mcguire, 1983, Prostaglandins.

Identification and Characterization of GAL-021 as a Novel Breathing Control Modulator

D. Macintyre, D. Ritchie, R. Wardle, 2015, Anesthesiology.

Chapter 6. Pulmonary and Anti-Allergy Drugs

D. Ritchie, S. Bell, R. Capetola, 1979 .

Reticulocyte measurements as a bioassay for erythropoietin.

J. Natarajan, D. W. Anderson, D. Ritchie, 1994, Journal of pharmaceutical and biomedical analysis.

Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.

D. Ritchie, C. Lau, D. Argentieri, 1997, Prostaglandins, leukotrienes, and essential fatty acids.

N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.

P. Connolly, S. K. Wetter, D. Ritchie, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and biological properties of RWJ 22108, a bronchoselective calcium channel blocker.

D. Ritchie, J. Dodd, J. B. Moore, 1993, Drug design and discovery.

Cytokine-modulating activity of tepoxalin, a new potential antirheumatic.

D. Ritchie, C. Lau, R. Plante, 1995, International journal of immunopharmacology.

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.

D. Ritchie, Zhengyin Yan, G. Caldwell, 2001, Current topics in medicinal chemistry.

Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A.

D. Ritchie, L. Zhou, C. Lau, 1994, Journal of immunology.

Robotic assay of sphingomyelinase activity for high throughput screening.

D. Ritchie, D. Argentieri, A. Barbone, 2000, Methods in enzymology.

High-throughput cytochrome p450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns.

Sean X Peng, D. Ritchie, A. Barbone, 2003, Rapid communications in mass spectrometry : RCM.

Evaluation of the anaphylactoid activity of a new LHRH antagonist.

D. Hahn, D. Ritchie, C. Bowers, 1988, Life sciences.

Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.

D. Ritchie, S. Beers, M. Singer, 1997, The Journal of pharmacology and experimental therapeutics.

Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.

D. W. Anderson, D. Ritchie, M. Wachter, 1994, The Journal of pharmacology and experimental therapeutics.

Evaluation of calcium entry blockers in several models of immediate hypersensitivity.

D. Ritchie, C. M. Bishop, S. Levinson, 1984, The Journal of pharmacology and experimental therapeutics.

Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.

D. Ritchie, D. Hlasta, M. Wachter, 2004, Bioorganic & medicinal chemistry letters.

Flunarizine and verapamil: effects on central nervous system and peripheral consequences of cytotoxic hypoxia in rats.

D. Ritchie, B. Dubinsky, J. N. Sierchio, 1984, Life sciences.

Novel 6-Oxo-6-naphthylhexanoic Acid Derivatives with Anti-Inflammatory and 5-Lipoxygenase Inhibitory Activity.

D. Ritchie, W. Murray, M. Wachter, 1991 .